Bortezomib for AL amyloidosis: moving forward

被引：10
作者：
Dimopoulos, Meletios A. [1 ]
Kastritis, Efstathios [1 ]
机构：
[1] Univ Athens, Sch Med, GR-10679 Athens, Greece
来源：
BLOOD | 2011年 / 118卷 / 04期
关键词：
DEXAMETHASONE;
D O I：
10.1182/blood-2011-05-355115
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Reece et al report that single-agent bortezomib resulted in hematologic responses in two-thirds of patients with relapsed Light chain (AL) amyloidosis, including complete responses in one-third, while more than 75% of patients had response duration of more than or equal to 1 year.
引用
收藏
页码：827 / 828
页数：2
相关论文
共 11 条
[1]   The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition [J].
Bianchi, Giada ;
Oliva, Laura ;
Cascio, Paolo ;
Pengo, Niccolo ;
Fontana, Francesca ;
Cerruti, Fulvia ;
Orsi, Andrea ;
Pasqualetto, Elena ;
Mezghrani, Alexandre ;
Calbi, Valeria ;
Palladini, Giovanni ;
Giuliani, Nicola ;
Anderson, Kenneth C. ;
Sitia, Roberto ;
Cenci, Simone .
BLOOD, 2009, 113 (13) :3040-3049
[2]   How I treat amyloidosis [J].
Comenzo, Raymond L. .
BLOOD, 2009, 114 (15) :3147-3157
[3]  
KASTRITIS E, 2010, ASH ANN M, V116, P3048
[4]   Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone [J].
Kastritis, Efstathios ;
Anagnostopoulos, Athanasios ;
Roussou, Maria ;
Toumanidis, Savvas ;
Pamboukas, Constantinos ;
Migkou, Magdalini ;
Tassidou, Anna ;
Xilouri, Irini ;
Delibasi, Sossana ;
Psimenou, Erasmia ;
Mellou, Sofia ;
Terpos, Evangelos ;
Nanas, John ;
Dimopoulos, Meletios A. .
HAEMATOLOGICA, 2007, 92 (10) :1351-1358
[5]   Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis [J].
Kastritis, Efstathios ;
Wechalekar, Ashutosh D. ;
Dimopoulos, Meletios A. ;
Merlini, Giampaolo ;
Hawkins, Philip N. ;
Perfetti, Vittorio ;
Gillmore, Julian D. ;
Palladini, Giovanni .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :1031-1037
[6]   Molecular mechanisms of amyloidosis [J].
Merlini, G ;
Bellotti, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06) :583-596
[7]   Dangerous small B-cell clones [J].
Merlini, Giampaolo ;
Stone, Marvin J. .
BLOOD, 2006, 108 (08) :2520-2530
[8]   Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study [J].
Reece, Donna E. ;
Hegenbart, Ute ;
Sanchorawala, Vaishali ;
Merlini, Giampaolo ;
Palladini, Giovanni ;
Blade, Joan ;
Fermand, Jean-Paul ;
Hassoun, Hani ;
Heffner, Leonard ;
Vescio, Robert A. ;
Liu, Kevin ;
Enny, Christopher ;
Esseltine, Dixie-Lee ;
van de Velde, Helgi ;
Cakana, Andrew ;
Comenzo, Raymond L. .
BLOOD, 2011, 118 (04) :865-873
[9]   Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study [J].
Reece, Donna E. ;
Sanchorawala, Vaishali ;
Hegenbart, Ute ;
Merlini, Giampaolo ;
Palladini, Giovanni ;
Fermand, Jean-Paul ;
Vescio, Robert A. ;
Liu, Xiangyang ;
Elsayed, Yusri A. ;
Cakana, Andrew ;
Comenzo, Raymond L. .
BLOOD, 2009, 114 (08) :1489-1497
[10]   Bortezomib in the treatment of AL amyloidosis: targeted therapy? [J].
Sitia, Roberto ;
Palladini, Giovanni ;
Merlini, Giampaolo .
HAEMATOLOGICA, 2007, 92 (10) :1302-1307
12